Prognostic value of the C-reactive protein/albumin ratio in patients with laryngeal squamous cell carcinoma. 2017

Shi-Tong Yu, and Zhiwei Zhou, and Qian Cai, and Faya Liang, and Ping Han, and Renhui Chen, and Xiao-Ming Huang
Department of Otolaryngology, Head and Neck Surgery; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.

OBJECTIVE The present study was designed to retrospectively evaluate the prognostic value of the C-reactive protein/albumin (CRP/ALB) ratio in laryngeal squamous cell carcinoma (LSCC). METHODS One hundred and twenty-nine newly diagnosed LSCC patients admitted between May 2006 and October 2011 were retrospectively reviewed. Their serum CRP and ALB were quantified preoperatively. The relationship between the CRP/ALB ratio and the clinicopathologic features was analyzed. Receiver operating characteristic curve was used to calculate the prognostic value of the CRP/ALB ratio. Then, the Cox proportional hazards model was used in univariate and multivariate analyses to identify significant prognostic factors associated with disease-free survival and overall survival. RESULTS The cutoff value for CRP/ALB ratio was 0.047. An elevated CRP/ALB ratio was significantly associated with nodal metastasis, late disease stage, and recurrence. Also, high values of CRP/ALB ratio were significant predictors for poor overall survival and disease-free survival on multivariate analysis. CONCLUSIONS Pretreatment CRP/ALB ratio may be a significant prognostic marker in LSCC.

UI MeSH Term Description Entries

Related Publications

Shi-Tong Yu, and Zhiwei Zhou, and Qian Cai, and Faya Liang, and Ping Han, and Renhui Chen, and Xiao-Ming Huang
October 2016, Journal of the Korean Association of Oral and Maxillofacial Surgeons,
Shi-Tong Yu, and Zhiwei Zhou, and Qian Cai, and Faya Liang, and Ping Han, and Renhui Chen, and Xiao-Ming Huang
January 2020, PeerJ,
Shi-Tong Yu, and Zhiwei Zhou, and Qian Cai, and Faya Liang, and Ping Han, and Renhui Chen, and Xiao-Ming Huang
December 2019, Minerva anestesiologica,
Shi-Tong Yu, and Zhiwei Zhou, and Qian Cai, and Faya Liang, and Ping Han, and Renhui Chen, and Xiao-Ming Huang
December 2025, Discover oncology,
Shi-Tong Yu, and Zhiwei Zhou, and Qian Cai, and Faya Liang, and Ping Han, and Renhui Chen, and Xiao-Ming Huang
April 2020, Clinics and research in hepatology and gastroenterology,
Shi-Tong Yu, and Zhiwei Zhou, and Qian Cai, and Faya Liang, and Ping Han, and Renhui Chen, and Xiao-Ming Huang
January 2019, Frontiers in oncology,
Shi-Tong Yu, and Zhiwei Zhou, and Qian Cai, and Faya Liang, and Ping Han, and Renhui Chen, and Xiao-Ming Huang
May 2015, BMC cancer,
Shi-Tong Yu, and Zhiwei Zhou, and Qian Cai, and Faya Liang, and Ping Han, and Renhui Chen, and Xiao-Ming Huang
January 2015, International journal of clinical and experimental pathology,
Shi-Tong Yu, and Zhiwei Zhou, and Qian Cai, and Faya Liang, and Ping Han, and Renhui Chen, and Xiao-Ming Huang
December 2018, Medicine,
Shi-Tong Yu, and Zhiwei Zhou, and Qian Cai, and Faya Liang, and Ping Han, and Renhui Chen, and Xiao-Ming Huang
December 2022, European review for medical and pharmacological sciences,
Copied contents to your clipboard!